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PALIFERMIN USE IN ADOLESCENT STEM CELL TRANSPLANT PATIENTS:
CASE REPORTS
Williams, D.1, Deoras, R.1, Seaton, A.2, Makonnen, T.3 1Children’s
National Medical Center, Washington, DC; 2University of Maryland;
3Virginia Commonwealth University
Purpose: This is a case series report of two adolescent stem cell
transplant patients who received palifermin therapy to decrease the
duration and severity of oral mucositis.
Background: Oral mucositis, an injury of the oral mucosa found
most comonly in patients receiving chemotherapy and/or radiation,
is one of the most debilitating toxicities associated with stem cell
transplantation. Oral mucositis has been associated with the need
for total parenteral nutrition, longer hospital admissions with an in-
crease in hospital charges, and an increased risk of mortality within
the first 100 days post-transplant.
Several risk factors have been identified for increased risk of severe
oral mucositis. Risk factors that may predispose patients to more se-
vere oral mucositis include alkylator agent chemotherapy stem cell
preparative regimens, radiation containing preparative regimens,
and herpes simplex virus.
Palifermin (Kepivance), a human keratinocyte growth factor, has
been used to decrease the incidence and severity of oral mucositis.
Palifermin is not FDA-approved for pediatric patients and reports
on its use in the pediatric hematopoietic stem cell transplant patient
population are limited.
This is a report of two cases of palifermin use in adolescent stemTable. Palifermin Results
Patient
Duration of
Mucositis (Days)
Most Severe WHO
Grade Oral Mucositis**
Able to Take Oral
Solids During Mucositis (Days) BMT Prep Regimen Transplant Type
1 4 2 4/4 BEAM, Radiation Augologous
2 11 1* 8/11 Fludarabine, Cyclophoshpamide, Total Body
Irradiation, Focal Mandible Radiation
Cord Blood
*Throat Pain, Abdominal Pain, No Oral Ulceration.
**World Health Oraganization.cell transplant patients. The observed patients include a 14 year-old
who received a double cord blood allogeneic transplant following
a fludarabine, cyclophosphamide total body irradiation and focal ra-
diation prep, and a 14 year-oldwho received an autologous transplant
following a BEAM (Carmustine, Etoposide, Cytarabine, Melphalan)
and focal radiation prep. In both cases, the use of palifermin pre-
vented progression to severe, grade three or four mucositis.
Results:
Conclusion: Palifermin is an effective alternative to decrease sever-
ity of oral mucositis in adolescent stem cell transplant patients.
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PHARMACISTS’ ROLE IN IMPLEMENTATION OF AN ALLOGENEIC HPC
TRANSPLANT PROGRAM
Lee, K.J., Wong-Yu, F.H., Chow, V. USC Norris Comprehensive Cancer
Center, Los Angeles, CA
The autologous hematopoietic progenitor cell (HPC) transplant
program at USC Norris Comprehensive Cancer Center has been in
practice since 1987. In 2011, the planning and implementation of al-
logeneic HPC transplant program began with efforts of a multi-dis-
ciplinary team of experts providing collaborative clinical practice.
Pharmacists played a key role especially in the creation of policies,
preprinted orders, drug therapy management, and education.
Pharmacists reviewed medications for the conditioning regimen,
graft-versus-host disease (GVHD) prophylaxis, and various support-
ive cares by evaluating literature and bench-markingwith otherHPC
transplant centers. The goal was to ensure evidence-based practices
as well as to meet current regulatory standards. The pharmacists’ dil-
igence in procuring and ensuring adequate supply of medications as
well as their timely delivery to patients was crucial in light of recent
drug shortage challenges. Instituting standing orders for electrolyte
replacements, STAT antibiotics, GVHD prophylaxis, and keeping
the majority of medications as floor stock items enabled us to achieve
this goal. In order to administer high-dose chemotherapy safely, twopharmacists independently verify chemotherapy doses against the
standardized regimen listed on the orders.Monographs for keymed-
ications containing information such as drug stability, compatibility,
and special handling were compiled to provide a quick reference and
educational tool for pharmacists.
By participating in daily patient rounds, pharmacists monitored
patients’ clinical status closely, managed complications of high-
dose chemotherapy and adjusted levels of anti-GVHD medications
in a timely manner. To ensure optimal therapeutic dosing with min-
imal toxicity, busulfan pharmacokinetics was implemented under
joint leadership of pharmacists and nurses. In addition, pharmacists
played a major role in educating nurses on high-dose chemotherapy,
immunosuppressive agents and the supportive care for infection,mu-
cositis, nausea and vomiting in allogeneic HPC transplant patients.
In conclusion, pharmacists played a critical role by providing their
expertise in the management of complex drug therapy, monitoring
busulfan pharmacokinetics, educating their peers and thus, contrib-
uting to the success of the program.
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AN EFFECTIVE HEMATOPOIETIC STEM CELL MOBILIZATION ALGORITHM
FOR ADDING PLERIXAFOR TO G-CSF FOR MULTIPLE MYELOMA PA-
TIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION
LaPorte, J.1, Solomon, S.1, Bashey, A.1, Holland, K.1, Morris, L.1,
Sizemore, C.1, Sanacore, M.1, Mihelic, R.1, Leech, M.1, Penland, P.2,
Xang, Z.3 1Northside Hosptial, Atlanta, GA; 2Northside Hospital, At-
lanta, GA; 3Georgia State University, Atlanta, GABackground: Autologous hematopoietic stem cell transplantation
(ASCT) has become an integral part of the treatment for multiple
myeloma (MM). In addition, it is standard practice to collect suffi-
cient stem cells for more than one transplant. Therefore, it is critical
to have an effective mobilization strategy in order to efficiently col-
lect enough CD34+ cells. Administering granulocyte-colony stimu-
lating factor (G-CSF) alone to MM patients can produce sufficient
CD34+ yields in the majority of patients. However, some patients
may require. 4 apheresis days to achieve those yields or fail to col-
lect enough CD34+ cells for ASCT. Plerixafor (P) can increase the
average daily CD34+ yields by 3-fold. Since the majority of patients
can collect withG-CSF alone, an algorithmwas developed in 2009 to
judiciously administer P only to those patients at higher perceived
risk for mobilization failure.
Methods:G-CSF 10mcg/kg/day was administered SC from day 1 to
4.On day 4, a peripheral absoluteCD34+ cell count was drawn. If the
absolute CD34+ count was$ 12 cells/mm3 then apheresis started on
day 5. If the absolute CD34+ count on day 4 was\ 12 cells/mm3 P
240mcg/kg was administered SC the evening prior to apheresis be-
ginning on day 5. During apheresis, if the CD34+ yield was \
1.0x106 CD34+/kg or 50%\the previous collection, Pwas initiated.
The minimum collection yield for all patients was 4.0x106 CD34+/
kg. The maximum number of apheresis days was 5.
Results: From10/09 - 5/11, 68MMpatients weremobilizedwithG-
CSF +/- P. 93%(63/68) of patients achieved minimum collection
yield of 4.0x106CD34+/kg. 99%ofpatients achieved a yield of at least
2.0x106 CD34+/kg. 44% (30/68) of the patients required at least 1
dose of P with the majority requiring it prior to the first apheresis
(83%). Themedian days of apheresis was 2 (1-5). The overall average
yield on the first apheresis day and total yieldwas 4.35x106CD34+/kg
(95%CI+/- 0.64) and 8.71x106CD34+/kg (95%CI+/- 0.93), respec-
tively. 60% (41/68) and 76% (52/68) of patients collected$ 6.0x106
CD34+/kg in# 2 days and# 4 days of apheresis, respectively.
Conclusion: Adding P to G-CSF based upon a day 4 CD34+ count
and collection yields is an effective strategy to mobilize CD34+ cells.
